There is a lot of commentary about the poor performance of the biotech section in 2021 mainly due a policy change of the Biden administration. The view is that the biotech sector is now deeply undervalued and the policy changes were overreacted. There’s a view that 2022 will be a good year for biotech in the US and for us it’s should be as well with Lag-3 coming to the forefront hopefully BMS will get FDA approval in March for their Lag-3 drug. I’ve top up considerably at .47 cents to me it’s the biggest Christmas gift !!!
Trust everyone had a great Christmas and I personally feel 2022 will be a much better year for the Immutep share price….
Media, page-26
-
- There are more pages in this discussion • 357 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 41.0¢ | 39.5¢ | $1.515M | 3.783M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 115519 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 37481 | 2 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |